Tagged with Shortages

Global Several macro-trends affected the pharmaceutical industry in 2022, impacting its inventory position, writes Matthew Bardell, managing director of specialist inventory consultants nVentic. Bardell highlights findings in a recent report – including the fact that despite widely-reported medicine shortages, Big Pharma’s inventories grew significantly last year – and calls for a…

Europe In conversation with PharmaBoardroom Christoph Stoller and Adrian Van den Hoven of Medicines for Europe, the association representing the European generics, biosimilar and value-added-medicines industry, highlighted their members’ rapid response to the COVID-19 crisis and why Europe-wide reform is needed to avoid future medicine shortages and strengthen the supply chain.…

Brazil The editorial team at Panorama Farmaceutico explain why coordinated action is needed within Brazilian pharma to reduce dependence on API imports from abroad and increase medical sovereignty. *   The COVID-19 pandemic has exposed the global pharmaceutical industry’s dependence on markets such as India, the source of about 20 percent…

Belgium Xavier De Cuyper introduces the Federal Agency for Medicines & Health Products (FAMHP) and the essential role it plays in Belgium’s healthcare regulatory framework since being founded in 2007. De Cuyper goes on to shed light on the organization’s several ongoing priorities which include embracing digital trends, unlocking the potential…

Belgium On 3 February 2020 the Act of 20 December 2019 amending various legal provisions concerning shortages of medicinal products was published in the Official Gazette. Except for Articles 2 and 4, which entered into force on 31 January 2020, the act’s provisions entered into force on 13 February 2020. In our view, the…

Mexico Rafael Gual Cosío, director general of the Cámara Nacional de la Industria Farmacéutica (CANIFARMA), the umbrella industry association for the healthcare sector in Mexico, shares his perspectives on the complex situation in the Mexican healthcare landscape today; the importance of positive and open working relationships between the public and private…

Czech Republic Medicine shortages are a European-wide issue. In 2016, the European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) formed a task force to investigate availability issues, including medicines that are authorized but not marketed, and supply chain disruptions in order to improve the continuity of medicine supply across Europe.  …

Czech Republic Tomáš Votruba of the Association of Full-Line Wholesalers (AVEL), which gathers the three major players of the pharmaceutical distribution market in the Czech Republic, gives an overview of the current priorities and challenges for wholesalers, and how he advocates for the interests of his members by working closely with the…

Russia Russia is facing a drug shortage crisis which is having a particular impact on patients with life-threatening conditions. A combination of geopolitical and bureaucratic issues are restricting the flow of medications to the patients who need them the most.   An alarming shortage of medicines in Russia is driving some…

Czech Republic The Czech Republic’s Minister of Health,  Adam Vojtěch, is the youngest in the country’s history and has set out an ambitious reform programme to improve the state of the Czech healthcare system.   In my office, I will actively seek to fulfil the key points of my election program –…

Hungary Like many of its European counterparts, Hungary is suffering from medicine shortages. Vaccines, vitamins, and orphan drugs are some of the most affected areas and oncology patients are now also at risk.   An Increasing Burden Over 14,000 types of pharmaceuticals are unavailable in Hungarian pharmacies, which is placing an…

Generics Christoph Stoller, general manager for Austria and Germany at Teva was recently elected president of Medicines for Europe, the continent-wide association for the generics and biosimilars industries. Stoller plans to focus his efforts on improving access to generics and biosimilars in Europe, as well as tackling the damaging issue of…